Efficacy, Safety and Evolution of Cardiovascular Parameters in Renal Transplant Recipients
Status:
Completed
Trial end date:
2014-10-30
Target enrollment:
Participant gender:
Summary
The purpose of this study was to determine whether an early Calcineurin Inhibitor (CNI) to
everolimus conversion at 10-14 weeks post transplantation improves renal allograft function
without compromising efficacy compared to standard CNI treatment in de novo renal allograft
recipients. In addition, the study was designed to evaluate the impact of a CNI-free regimen
on evolution of cardiovascular parameters in de novo renal allograft recipients